REGN
Regeneron Pharmaceuticals Inc
784.90$
-0.6%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +45.5% | +18.4% | +20.8% | +14.3% | +17.2% | +8.1% | +89.1% | -24.3% | +7.8% | +8.3% | +1.0% | |
| – | +91.5% | -23.7% | +32.5% | +9.3% | +80.2% | +73.3% | +100.9% | -37.4% | -48.2% | +123.0% | +6.6% | |
| – | +41.9% | +22.9% | +20.1% | +14.6% | +12.8% | +0.8% | +86.9% | -21.6% | +16.9% | 0.0% | +0.1% | |
| – | +27.5% | +26.6% | +1.1% | +5.3% | +38.9% | -17.7% | +4.9% | +16.6% | +45.3% | +17.9% | +11.8% | |
| – | +66.1% | +40.4% | +12.1% | +17.9% | +17.9% | -26.6% | +35.6% | +15.9% | +20.7% | +15.7% | -8.6% | |
| – | +38.5% | +31.3% | +5.1% | +10.2% | +30.2% | -26.8% | +23.5% | +15.5% | +39.1% | +16.6% | +5.1% | |
| – | +49.3% | +6.3% | +56.3% | +21.9% | -12.8% | +61.9% | +150.1% | -39.8% | -24.9% | -1.4% | -10.3% | |
| – | -61.9% | -49.5% | +249.1% | +12.3% | +7.1% | +88.4% | +0.7% | +3.7% | +22.9% | -24.4% | -20.7% | |
| – | +57.9% | +8.5% | +56.3% | +22.9% | -4.9% | +56.9% | +144.7% | -47.9% | -13.6% | +13.8% | +9.4% | |
| – | +37.7% | -26.3% | +102.6% | -87.6% | +187.2% | -5.1% | +320.8% | -58.4% | -52.8% | +49.5% | +97.6% | |
| – | +82.7% | +40.8% | +33.8% | +104.0% | -13.4% | +66.0% | +129.9% | -46.3% | -8.9% | +11.6% | +2.1% | |
| – | +48.9% | +8.2% | +55.0% | +20.6% | -9.8% | +69.5% | +135.7% | -45.6% | -23.1% | +31.4% | +9.4% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.